biomarker platform News
-
PERKINELMER LAUNCHES BIOXPRESSION™ BIOMARKER PLATFORM AT THE ASMS CONFERENCE ON MASS SPECTROMETRY
Untitled Document Biomarker Platform Provides a Complete Solution for Disease Biomarker Discovery and Screening SAN ANTONIO, Texas – PerkinElmer Inc. (NYSE: PKI ), a leading provider in genetic screening, drug discovery, life science research, and analytical solutions, today announced the launch of its BioXPRESSION™ Biomarker discovery and screening platform at the 53rd ...
-
GI Innovation Signs MoU with CellKey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...
-
GI Innovation singed MoU with CellKey for joint biomarker research for development of next generation innovative immuno-oncology.
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...
-
Bodyport Appoints John Lipman as Chief Executive Officer
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, today announced the appointment of medtech industry veteran, John Lipman, as Chief Executive Officer. Bodyport co-founder, Corey Centen, will continue as President and also serve as Chief Technology Officer (CTO) of the company. Lipman’s appointment comes as Bodyport prepares for ...
-
Bodyport raises $11.2 million in Series A funding to launch virtual cardiac clinic
Bodyport, the digital health company focused on the detection and management of heart disease, today announced the close of an $11.2 million Series A investment round. Boehringer Ingelheim Venture Fund (BIVF) led the round and was joined by existing investors Playground Global, Initialized Capital, Y Combinator and Hardware Club, as well as new investors Kapor Capital and Regah Ventures. The ...
-
Bodyport Announces Appointment of Jim Pursley to Board of Directors
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors. “I am excited to join the Bodyport Board of Directors as they reimagine care for patients living with complex chronic conditions. Bodyport’s focus on the patient has driven them to ...
-
Altoida Appoints Neuroscience Pioneer Dr. Antontella Santuccione Chadha as Chief Medical Officer
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer. In this new role, Dr. Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize ...
-
Atmo Biosciences’ ingestible gas-sensing capsule to be used in Swedish IBS trial led by Professor Magnus Simrén
Atmo Biosciences’ world-first ingestible gas-sensing capsule is being used in a clinical trial led by renowned gastroenterologist Professor Magnus Simrén currently underway at Sweden’s University of Gothenburg. The trial named “The effects of carbohydrates in irritable bowel syndrome” is using the Atmo Gas Capsule digital biomarker platform to profile gases within ...
-
Bodyport Appoints Amit Rushi as Chief Commercial Officer and Phyllis Whiteley, Ph.D. as Chair of the Board of Directors
Bodyport, the digital health company focused on the detection and management of heart disease, today announced that it has named Amit Rushi as Chief Commercial Officer (CCO) and Phyllis Whiteley as Chair of the Board of Directors. With this newly created role, Amit Rushi will serve as part of the executive team and prepare the organization for commercialization and growth. As Chair of the Board, ...
-
Mission Based Media Launches Alzheimer`s Podcast, the Newest Podcast Miniseries on Health Unmuted
Mission Based Media, a leader in podcasts about health, care and well-being, has launched a new podcast miniseries about Alzheimer's disease. The Alzheimer's Podcast miniseries provides insights and information for those who are diagnosed with Alzheimer's disease and the people who care about them. The miniseries was created with support from Altoida, a leading platform to improve drug ...
-
Specific Diagnostics Announces the Results of Two Studies at Hospitals Within AP-HP (Assistance Publique-Hopitaux de Paris) Evaluating Performance of the Reveal Rapid AST System
Specific Diagnostics today announced results from two studies conducted in the Paris Teaching Hospital System (Assistance Publique-Hôpitaux Paris, AP-HP), Europe’s largest hospital network, reporting performance of the Reveal rapid antibiotic susceptibility testing (AST) system. Both studies, which comprised approximately 225 samples in total, found the same levels of accuracy ...
-
Bodyport Receives FDA Clearance for the Bodyport Cardiac Scale
Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug Administration (FDA) 510(k) clearance. This innovative solution enables people with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess ...
-
PERKINELMER AND PREDICTIVE DIAGNOSTICS ANNOUNCE DISCOVERY OF BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE
Results of Joint Study Presented at the American Association for Clinical Chemistry Conference BOSTON & VACAVILLE, CALIFORNIA , April 19, 2005 – PerkinElmer Inc. (NYSE: PKI ), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced ...
-
Assessing Heart Function and Fluid Status with Cardiac Scales: Interview with John Lipman, CEO, and Corey Centen, Founder, Bodyport
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. The scales can detect these signals through the feet when a patient steps onto the device. The technology is intended to be convenient and requires only 20 seconds each morning, and should easily lend itself to ...
-
Alzheimer’s Drug Discovery Foundation’s diagnostics accelerator announces first digital biomarker research award and data sharing platform
Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos ...
-
Showcase
Empatica partnering with U.S. Army MRDC to deploy COVID-19 early detection wearable
BOSTON, Nov. 6, 2020 /PRNewswire/ -- Empatica has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to deploy a wearable and algorithm that enable the early and pre-symptomatic detection of COVID-19. The project's focus is on protecting the health of the general population by preventing outbreaks via early detection and alerting. Empatica's Aura algorithm gives a ...
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
You`re invited to our webinar `How to Screen Binding Kinetics in 3 Easy Steps with the New EzPlex System`.
During this webinar you will learn how the new features of the fully-automated EzPlex system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ideal for biomarker discovery, biotherapeutics research, antibody and aptamer production, protein analysis, and cellular ...
-
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis.
Join us on April 8th, 2015 to learn more about the capabilities of XelPleX for multiplex label-free interaction analysis. During this webinar you will learn how the new features of the fully-automated XelPleX system improves label-free analysis by providing high throughput molecular profiling and affinity ranking in 3 easy steps. In addition, we will provide examples how the current platform is ...
-
CD Genomics: The Biomedical Bioinformatics Platform Unveils Biomarker and Target Discovery Data Analysis Service
The Biomedical Bioinformatics Platform belongs to CD Genomics and has a good reputation for assisting researchers with data analysis challenges, including NGS data processing, analysis, interpretation, and general genomic data analysis, as well as data mining, statistical modeling, data integration, information science, database construction, and management. Recently, the company announced the ...
By CD Genomics
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you